Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / COM
-
Number of holders
-
22
-
Total 13F shares, excl. options
-
1.15M
-
Shares change
-
+55.2K
-
Total reported value, excl. options
-
$5.54M
-
Value change
-
+$289K
-
Put/Call ratio
-
0.01
-
Number of buys
-
8
-
Number of sells
-
-8
-
Price
-
$4.82
Significant Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q1 2023
26 filings reported holding GANX - Gain Therapeutics, Inc. - COM as of Q1 2023.
Gain Therapeutics, Inc. - COM (GANX) has 22 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.15M shares
.
Largest 10 shareholders include GREENLIGHT CAPITAL INC (547K shares), GEODE CAPITAL MANAGEMENT, LLC (94.2K shares), CM Management, LLC (90K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (60K shares), PRELUDE CAPITAL MANAGEMENT, LLC (58.1K shares), VANGUARD GROUP INC (52.6K shares), Royal Bank of Canada (39K shares), RENAISSANCE TECHNOLOGIES LLC (38.7K shares), BlackRock Inc. (24.8K shares), and RAYMOND JAMES & ASSOCIATES (20K shares).
This table shows the top 22 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.